ClinicalTrials.gg
RecruitingNCT07455383Brilliance NT1Updated Nov 17, 2026

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

A Phase 3 interventional study of ALKS 2680 Dose 1 and ALKS 2680 Dose 2 in Narcolepsy Type 1, sponsored by Alkermes, Inc.. Recruiting at 66 sites in 15 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Alkermes, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 17, 2026First sites in 6 new countriesSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 85 studies in Narcolepsy with a site in United States — 19 open to participants now, 20 under way, 8 of them phase 3. Narcolepsy · United States.

Planned enrollment
25th of 69
150 · median 93
Started
2026
with 9 others
Phase 3
21 of 85
4 open now
Primary completion
2027-05
later than 5 of 19 live
Registered
78th of 85
by date
Lead sponsor
4 of 85
Alkermes, Inc.

Among the 85 studies in Narcolepsy with a site in United States, this one is the 25th largest by planned enrollment of the 69 interventional ones that give a count, is one of 10 that started in 2026, is one of 21 in phase 3, reaches primary completion later than 5 of the 19 other live ones, and was the 78th registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

19 of the 85 studies in Narcolepsy with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Narcolepsy with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.

03

Conditions studied

  • Narcolepsy Type 1

Keywords

  • Brillance
  • Narcolepsy
  • Narcolepsy Type 1
  • Sleep Disorders
  • Fatigue
  • Cataplexy
  • ALKS 2680
  • Alixorexton
  • Orexin-2 receptor agonist
  • excessive daytime sleepiness
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets the diagnostic criteria of NT1 according to ICSD-3-TR guidelines, confirmed by diagnostic evaluations (either PSG/MSLT* or CSF hypocretin-1 level).

Exclusion criteria

Exclusion Criteria:

  • Has another comorbid sleep disorder or condition that may influence the sleep-wake cycle.
  • Has a history or presence at Visit 1 of other (treated or untreated) illness, disease, abnormality, or surgical procedure that, in the opinion of the Investigator, might compromise participant safety, interfere with any study assessment, or affect the participant's ability to complete the study.
  • Is currently enrolled in another interventional clinical trial or has received any drug or used any interventional investigational device within 30 days prior to Visit 1. Participants previously enrolled in Study ALKS 2680-201 are not eligible for enrollment.
  • Is currently pregnant, breastfeeding, or is planning to become pregnant during the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
150 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Placebo arm

    Drug: Placebo

  • Experimental
    ALKS 2680 Dose 1

    Oral tablet containing ALKS 2680

    Drug: ALKS 2680 Dose 1

  • Experimental
    ALKS 2680 Dose 2

    Oral tablet containing ALKS 2680

    Drug: ALKS 2680 Dose 2

Interventions

  • DrugALKS 2680 Dose 1

    Participants will receive ALKS 2680 tablets, orally, daily, for 12 weeks

    Also known as: Alixorexton

  • DrugALKS 2680 Dose 2

    Participants will receive ALKS 2680 tablets, orally, daily, for 12 weeks

    Also known as: Alixorexton

  • DrugPlacebo

    Participants will receive ALKS 2680-matching placebo tablets, orally, for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Change in mean sleep latency (MSL) on Maintenance of Wakefulness Test (MWT) from baseline to Week 12 by dose level

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Change in Epworth Sleepiness Scale (ESS) from baseline to Week 12 by dose level

    Time frame: Baseline to Week 12

  2. Weekly cataplexy rate (WCR) at Week 12 by dose level

    Time frame: Week 12

  3. Percentage of participants who achieve a status of "none" or "mild" on Patient Global Impression- Severity (PGI-S) scale (general disease) at Week 12 by dose level

    Time frame: Week 12

  4. Change in British Columbia Cognitive Complaints Inventory (BC-CCI) from baseline to Week 12 by dose level

    Time frame: Baseline to Week 12

  5. Change in number of lapses on Psychomotor Vigilance Task (PVT) from baseline to Week 12 by dose level

    Time frame: Baseline to Week 12

  6. Change in Patient-Reported Outcomes Measurement Information System - Fatigue 6a (PROMIS Fatigue 6a) from baseline to Week 12 by dose level

    Time frame: Baseline to Week 12

  7. Percentage of participants who achieve a status of "normal, not ill at all", "borderline ill", or "mildly ill" on Clinical Global Impression-Severity (CGI-S) (general disease) at Week 12 by dose level

    Time frame: Week 12

  8. Change in Narcolepsy Severity Scale for Clinical Trials (NSS-CT) from baseline to Week 12 by dose level

    Time frame: Baseline to Week 12

  9. Incidence of treatment emergent adverse events

    Time frame: Up to 14 weeks

07

Study locations

65 of 66 sites recruiting
  • Alkermes Investigational Site
    Cullman, Alabama 35055, United States
    Recruiting
  • Alkermes Investigational Site
    Phoenix, Arizona 85054, United States
    Recruiting
  • Alkermes Investigational Site
    Tucson, Arizona 85724, United States
    Recruiting
  • Alkermes Investigational Site
    Los Angeles, California 90025, United States
    Recruiting
  • Alkermes Investigational Site
    Boulder, Colorado 80301, United States
    Recruiting
  • Alkermes Investigational Site
    Brandon, Florida 33511, United States
    Recruiting
  • Alkermes Investigational Site
    Miami, Florida 33176, United States
    Recruiting
  • Alkermes Investigational Site
    Winter Park, Florida 32789, United States
    Recruiting
  • Alkermes Investigational Site
    Macon, Georgia 31210, United States
    Recruiting
  • Alkermes Investigational Site
    Kansas City, Kansas 66160, United States
    Recruiting
  • Alkermes Investigational Site
    Newton, Massachusetts 02459, United States
    Recruiting
  • Alkermes Investigational Site
    Lansing, Michigan 48911, United States
    Recruiting
  • Alkermes Investigational Site
    Novi, Michigan 48377, United States
    Recruiting
  • Alkermes Investigational Site
    St Louis, Missouri 63123, United States
    Recruiting
  • Alkermes Investigational Site
    Middletown, New Jersey 07748, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Alkermes Investigational Site
    New Hyde Park, New York 11042, United States
    Recruiting
  • Alkermes Investigational Site
    Charlotte, North Carolina 28210, United States
    Recruiting
  • Alkermes Investigational Site
    Cincinnati, Ohio 45245, United States
    Recruiting
  • Alkermes Investigational Site
    Wyomissing, Pennsylvania 19610, United States
    Recruiting
  • Alkermes Investigational Site
    Charleston, South Carolina 29425, United States
    Recruiting
  • Alkermes Investigational Site
    Columbia, South Carolina 29201, United States
    Recruiting
  • Alkermes Investigational Site
    Austin, Texas 78731, United States
    Recruiting
  • Alkermes Investigational Site
    San Antonio, Texas 78229, United States
    Recruiting
  • Alkermes Investigational Site
    Sugar Land, Texas 77478, United States
    Recruiting
  • Alkermes Investigational Site
    Madison, Wisconsin 53792, United States
    Recruiting
  • Alkermes Investigational Site
    Macquarie Park, New South Wales 2113, Australia
    Recruiting
  • Alkermes Investigational Site
    Bruges, 8000, Belgium
    Recruiting
  • Alkermes Investigational Site
    Edegem, 2650, Belgium
    Recruiting
  • Alkermes Investigational Site
    Ghent, 9000, Belgium
    Recruiting
  • Alkermes Investigational Site
    Namur, Belgium
    Recruiting
  • Alkermes Investigational Site
    Markham, Ontario L3R 1A3, Canada
    Recruiting
  • Alkermes Investigational Site
    Toronto, Ontario M5S 3A3, Canada
    Recruiting
  • Alkermes Investigational Site
    Montreal, Quebec H4J 1C5, Canada
    Recruiting
  • Alkermes Investigational Site
    Klecany, Central Bohemia 250 67, Czechia
    Recruiting
  • Alkermes Investigational Site
    Prague, Prague 128 21, Czechia
    Recruiting
  • Alkermes Investigational Site
    Helsinki, 00380, Finland
    Recruiting
  • Alkermes Investigational Site
    Bordeaux, 33076, France
    Recruiting
  • Alkermes Investigational Site
    Lyon, 69004, France
    Recruiting
  • Alkermes Investigational Site
    Montpellier, 34295, France
    Recruiting
  • Alkermes Investigational Site
    Nantes, 44093, France
    Recruiting
  • Alkermes Investigational Site
    Toulouse, 31059, France
    Recruiting
  • Alkermes Investigational Site
    Schwerin, Mecklenburg-Vorpommern 19053, Germany
    Recruiting
  • Alkermes Investigational Site
    Berlin, State of Berlin 10117, Germany
    Recruiting
  • Alkermes Investigational Site
    Bologna, 40139, Italy
    Recruiting
  • Alkermes Investigational Site
    Milan, 20127, Italy
    Recruiting
  • Alkermes Investigational Site
    Verona, 37134, Italy
    Recruiting
  • Alkermes Investigational Site
    Kitakyushu-shi, Fukuoka 802-0084, Japan
    Recruiting
  • Alkermes Investigational Site
    Osaka, Osaka 532-0003, Japan
    Recruiting
  • Alkermes Investigational Site
    tabashi City, Tokyo 173-8610, Japan
    Recruiting
  • Alkermes Investigational Site
    Shibuya-ku, Tokyo-To 151-0053, Japan
    Recruiting
  • Alkermes Investigational Site
    Shinjuku-Ku, Tokyo-To 162-0851, Japan
    Recruiting
  • Alkermes Investigational Site
    Kumamoto, 862-0954, Japan
    Recruiting
  • Alkermes Investigational Site
    Zwolle, Overijssel 8011, Netherlands
    Recruiting
  • Alkermes Investigational Site
    Heeze, 5591 VE, Netherlands
    Recruiting
  • Alkermes Investigational Site
    Krakow, Lesser Poland Voivodeship 30-721, Poland
    Recruiting
  • Alkermes Investigational Site
    Seongnam, 13620, South Korea
    Recruiting
  • Alkermes Investigational Site
    Seoul, 03080, South Korea
    Recruiting
  • Alkermes Investigational Site
    Seoul, 05505, South Korea
    Recruiting
  • Alkermes Investigational Site
    Suwon, 16247, South Korea
    Recruiting
  • Alkermes Investigational Site
    Vitoria-Gasteiz, Alava 01004, Spain
    Recruiting
  • Alkermes Investigational Site
    Barcelona, Barcelona 08036, Spain
    Recruiting
  • Alkermes Investigational Site
    Madrid, Madrid 28043, Spain
    Recruiting
  • Alkermes Investigational Site
    Madrid, Madrid 28046, Spain
    Recruiting
  • Alkermes Investigational Site
    Alzira, Valencia 46600, Spain
    Recruiting
  • Alkermes Investigational Site
    Kaohsiung City, 807, Taiwan
    Recruiting
  • Alkermes Investigational Site
    Taoyuan, 333, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for May 2027, 13 months after the start.

Of 14 phase 3 interventional studies under Narcolepsy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 6, 2026
StartActual
Apr 6, 2026
Primary completionEst.
May 2027
CompletionEst.
Jun 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
25 sites added, 1 site removed — first sites in Taiwan, Czechia, Finland, Germany, Poland and 1 more
All 6 countries

Taiwan, Czechia, Finland, Germany, Poland, South Korea

. Alkermes Investigational Site is now Terminated
Show 25 added (4 South Korea, 3 United States, 3 Spain, 2 Taiwan, 2 Czechia, 2 France, 2 Germany, 2 Italy, 1 Belgium, 1 Canada, 1 Finland, 1 Japan, 1 Poland)
  • Alkermes Investigational Site · Ghent, Belgium
  • Alkermes Investigational Site · Kaohsiung City, Taiwan
  • Alkermes Investigational Site · Tucson, United States
  • Alkermes Investigational Site · New Hyde Park, United States
  • Alkermes Investigational Site · Charleston, United States
  • Alkermes Investigational Site · Montreal, Canada
  • Alkermes Investigational Site · Klecany, Czechia
  • Alkermes Investigational Site · Prague, Czechia
  • Alkermes Investigational Site · Helsinki, Finland
  • Alkermes Investigational Site · Nantes, France
  • Alkermes Investigational Site · Toulouse, France
  • Alkermes Investigational Site · Schwerin, Germany
  • Alkermes Investigational Site · Berlin, Germany
  • Alkermes Investigational Site · Bologna, Italy
  • Alkermes Investigational Site · Milan, Italy
  • Alkermes Investigational Site · tabashi City, Japan
  • Alkermes Investigational Site · Krakow, Poland
  • Alkermes Investigational Site · Seongnam, South Korea
  • Alkermes Investigational Site · Seoul, South Korea
  • Alkermes Investigational Site · Seoul, South Korea
  • Alkermes Investigational Site · Suwon, South Korea
  • Alkermes Investigational Site · Madrid, Spain
  • Alkermes Investigational Site · Madrid, Spain
  • Alkermes Investigational Site · Alzira, Spain
  • Alkermes Investigational Site · Taoyuan, Taiwan
Show 1 removed
  • Alkermes Investigational Site · Madrid, Spain
across 2 updates, Oct 7, 2026 – Nov 17, 2026
Show all 2 updates
  1. Nov 17, 2026
    23 sites added, 1 site removed — first sites in Czechia, Finland, Germany, Poland and South Korea. Alkermes Investigational Site is now Terminated
    Show 23 added (4 South Korea, 3 United States, 3 Spain, 2 Czechia, 2 France, 2 Germany, 2 Italy, 1 Canada, 1 Finland, 1 Japan, 1 Poland, 1 Taiwan)
    • Alkermes Investigational Site · Tucson, United States
    • Alkermes Investigational Site · New Hyde Park, United States
    • Alkermes Investigational Site · Charleston, United States
    • Alkermes Investigational Site · Montreal, Canada
    • Alkermes Investigational Site · Klecany, Czechia
    • Alkermes Investigational Site · Prague, Czechia
    • Alkermes Investigational Site · Helsinki, Finland
    • Alkermes Investigational Site · Nantes, France
    • Alkermes Investigational Site · Toulouse, France
    • Alkermes Investigational Site · Schwerin, Germany
    • Alkermes Investigational Site · Berlin, Germany
    • Alkermes Investigational Site · Bologna, Italy
    • Alkermes Investigational Site · Milan, Italy
    • Alkermes Investigational Site · tabashi City, Japan
    • Alkermes Investigational Site · Krakow, Poland
    • Alkermes Investigational Site · Seongnam, South Korea
    • Alkermes Investigational Site · Seoul, South Korea
    • Alkermes Investigational Site · Seoul, South Korea
    • Alkermes Investigational Site · Suwon, South Korea
    • Alkermes Investigational Site · Madrid, Spain
    • Alkermes Investigational Site · Madrid, Spain
    • Alkermes Investigational Site · Alzira, Spain
    • Alkermes Investigational Site · Taoyuan, Taiwan
    Show 1 removed
    • Alkermes Investigational Site · Madrid, Spain
    + 1 other change: verification date
  2. Oct 7, 2026
    2 sites added — first site in Taiwan
    Show 2 added (1 Belgium, 1 Taiwan)
    • Alkermes Investigational Site · Ghent, Belgium
    • Alkermes Investigational Site · Kaohsiung City, Taiwan
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07455383
Lead sponsor
Alkermes, Inc.
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Apr 6, 2026
Primary completion
May 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Director, Clinical Trial Manager
Contact
clinicaltrials@alkermes.com
888-235-8008 (US Only)
Director, Clinical Trial Manager
Contact
clinicaltrials@alkermes.com
571-599-2702 (Global)
Medical Director, MD
study director · Alkermes, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion